Properties
What is it?
International Nonproprietary Name - ambroxol hydrochloride Clinical-pharmacological group: Pulmonology → Mucolytics and antitussives → Mucolytics and expectorants Composition 1 ml of solution contains: Active substance: 7.5 mg ambroxol hydrochloride. Excipients: Citric acid monohydrate (E330), Disodium hydrogen phosphate dihydrate (E339), Sodium chloride, Benzalkonium chloride, Purified water. Description Clear, colorless or slightly brownish solution. Pharmacotherapeutic group Expectorant, except in combination with antitussives. Mucolytics. Indications for use Expectorant therapy for acute and chronic diseases of the bronchi and lungs caused by impaired mucus formation and clearance. Method of administration and dosage Adults and children from 6 years of age: 2-3 ml of solution 1-2 times a day (equivalent to 15-22.5 mg of ambroxol hydrochloride 1-2 times a day). Lazolvan inhalation solution should not be taken for more than 4-5 days without consulting a doctor. Instructions for use Lazolvan inhalation solution can be used in various modern inhalation devices (e.g., compressor and ultrasonic), except for steam inhalers. Heating the solution up to 80°C for 10 minutes does not negatively affect its stability. Lazolvan inhalation solution can be mixed with physiological saline solutions and beta-sympathomimetics. Lazolvan inhalation solution cannot be mixed with cromoglicic acid. Furthermore, it is not recommended to mix the preparation with other solutions, for example, alkaline sea inhalation water, if the resulting mixture has a pH higher than 6.3. An increased pH value can lead to precipitation of the free base of ambroxol hydrochloride or turbidity of the solution. To achieve maximum humidification of the air from the inhaler, Lazolvan inhalation solution is mixed with physiological saline solution in a 1:1 ratio. The inhalation solution is isotonic, so it does not negatively affect mucous membranes. Nevertheless, inhalation itself can cause coughing, so it is recommended to breathe freely during inhalation. Before inhalation, the solution should be warmed to body temperature. Side effects Immune system disorders: Rare: hypersensitivity reactions Unknown: anaphylactic reactions, including anaphylactic shock, angioedema, itching. Nervous system disorders: Frequent: dysgeusia (altered taste sensation). Gastrointestinal disorders: Frequent: nausea, sensation of numbness in the oral cavity. Uncommon: vomiting, diarrhea, dyspepsia, abdominal pain, dry mouth. Rare: dry throat. Very rare: sialorrhea (excessive salivation). Respiratory, thoracic and mediastinal disorders: Frequent: sensation of numbness in the throat. Very rare: dyspnea and bronchospasm (usually in patients with hyperresponsiveness of the airways). Unknown: dyspnea (as a symptom of a hypersensitivity reaction). Skin and subcutaneous tissue disorders: Rare: rash, urticaria. Frequency unknown: severe skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). General disorders and administration site reactions: Uncommon: fever, mucous membrane reactions.